TORNTPHARM Q2 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,889 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
₹939 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a 9% revenue growth to INR 2,889 crore with 14% EBITDA growth to INR 939 crore in Q2 FY25. The outperformance was driven by strong branded business momentum, where India grew 13% (vs 8% IPM), Brazil surged 17% in CC, and Germany expanded with incremental tender wins. EBITDA margin expanded to 32.5%, aided by higher branded mix, though the CFO guided for 50-100bps annual improvement going forward. Insulin facility shutdown impacted ~INR 40 crore revenue, expected to recover in Q4. Field force expanded to 6,000 with 300 reps added; MR productivity targeted at INR 9.5-10 lakhs in 18 months. U.S. remains stable at $32mn with slow recovery expected over 2-3 years post FDA facility clearances. Net debt reduced by INR 900 crore in H1; company targets net cash position by FY26 with ~INR 250-300 crore annual CapEx. Key risks include insulin recovery timing, INR depreciation impact on Brazil/overseas, and muted volume growth in India IPM data versus management estimates.
Colored figures show movement against the previous available record.
Guidance to track
- Driven by operating leverage from branded businesses and reduced investment pace. Germany has tender visibility for 2 years; U.S. slow ramp-up will be margin positive.
- Expecting slow ramp-up as most ANDAs are old due to prior plant issues. Aim to make U.S. profitable (pre-R&D break-even currently) within 3 years.
- Torrent indicated annual CapEx guidance for the next 2-3 years. Debt repayment of INR 500-600 crore expected in H2 FY25.
- Management expects Brazil to continue growing faster than market (8-9% IPM) with 1-2 product launches per division annually and 5-10 generics launches per year.
Risks flagged
- Manufacturing facility at Indrad scheduled for release in December; Q4 recovery of ~INR 40 crore shortfall is dependent on smooth ramp-up. Any further delay could impact FY25 revenue guidance.
- Management explicitly guided 'stable to slightly increasing' U.S. revenues for 2-3 years, acknowledging limited ANDA pipeline due to prior plant issues. No meaningful ramp expected without lucky CDMO opportunities.
- Volume contribution remains low single-digit (~3%) despite management's view that market growth is underestimated by 2%. AIOCD data shows 0.2% volume vs Torrent's ~1%, suggesting potential market share capture ceiling.
- Management confirmed no manufacturing plans for GLP-1 products currently; relying on CMO business with Novo Nordisk. As India GLP-1 market develops, Torrent may miss out on this high-growth segment without in-house capabilities.
Key quotes
- I don't expect the U.S. to ramp up anywhere very fast in the next two years. So we do have a few which might be a unique product, but we cannot predict because it depends upon the number of competitors that show up, and if we get CDMO or not.
- As far as Germany is concerned, Germany is good, I would say, in terms of winning tenders, and there's good amount of visibility for the next two years.
- The only thing which is why it is not going up on relative basis is that the spend on the U.S., we had lowered, right, and because of the internal issues which we've had, so I don't see substantial increase in R&D at least over the next one year.
Research modules